Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Children's Hospital of Philadelphia

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
601
Shown on this page
12
Current sort
Recently updated
Campus scope
Children's Hospital of Philadelphia, Philadelphia, PA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Children's Hospital of Philadelphia, Philadelphia, PA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 97–108 of 601 matching trials with a site at Children's Hospital of Philadelphia, Philadelphia, PA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting No phase listed Observational

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT06131801
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma
Interventions
1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
0 Years to 38 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

NCT04258943
Site status not listed — check the official record
View directory record Official record
Conditions
Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia
Interventions
Bosutinib
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

NCT02912559
Site status not listed — check the official record
View directory record Official record
Conditions
Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Quality-of-Life Assessment
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1026
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

NCT02567435
Site status not listed — check the official record
View directory record Official record
Conditions
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma, Sclerosing Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma
Interventions
Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Temsirolimus, Vincristine Sulfate, Vinorelbine
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
355
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 210 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625
Site status not listed — check the official record
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
365 Days to 31 Years
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Active, not recruiting Phase 2 Interventional

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02981628
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Diagnostic Imaging Testing, Inotuzumab Ozogamicin, Leucovorin Calcium, Lumbar Puncture, Methotrexate, Pegaspargase, Vincristine
Drug · Procedure · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
156
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Recruiting No phase listed Observational

A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition

NCT06581146
Status at this site: Recruiting
View directory record Official record
Conditions
X-Linked Myotubular Myopathy
Interventions
No Intervention
Other
Lead sponsor
Astellas Gene Therapies
Industry
Eligibility
Up to 17 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Santa Monica, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Down Syndrome Obstructive Sleep Apnea

NCT06043440
Status at this site: Recruiting
View directory record Official record
Conditions
Down Syndrome, Obstructive Sleep Apnea
Interventions
Oxygen
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Ann Arbor, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Recruiting Phase 3 Interventional

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

NCT05821959
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Sensorineural Hearing Loss, Bilateral
Interventions
AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
Combination Product
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01896999
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
479
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of GlcNAc on Tear Production in NGLY1-CDDG

NCT05402345
Site status not listed — check the official record
View directory record Official record
Conditions
NGLY1 Deficiency
Interventions
GlcNAc-GlcN, Placebo
Drug · Other
Lead sponsor
Eva Morava-Kozicz
Other
Eligibility
1 Year to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 10:22 AM EDT
Recruiting Phase 3 Interventional

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

NCT05878860
Status at this site: Recruiting
View directory record Official record
Conditions
X-linked Retinoschisis
Interventions
ATSN-201
Biological
Lead sponsor
Atsena Therapeutics Inc.
Industry
Eligibility
5 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 10:22 AM EDT

About this Children's Hospital of Philadelphia institution page

What this page lists
ClinicalTrials.gov records that list Children's Hospital of Philadelphia in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.